Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

India is stepping into the billion-dollar weight-loss drug war! With Wegovy and Mounjaro already here, Biocon is quietly ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Earlier this week, semaglutide drugs Ozempic and Wegovy were made available for prescription in New Zealand. Semaglutide ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...